Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment

키워드

참고문헌 (30)

1. Cancer Genome Atlas Research Network, "Comprehensive molecular profiling of lung adenocarcinoma", Nature, 511, pp.543~550 (2014)
2. Hsu KH, "Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan", PLoS One, 10, pp.e0120852~ (2015)
3. Greenhalgh J, "First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous nonsmall cell lung cancer", Cochrane Database Syst Rev, (5) (2016)
4. Thongprasert S, "Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin", paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS), 2011, pp.6, 1872~1880
5. Jackman D, "Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancer", J Clin Oncol, 28, pp.357~360 (2010)
6. Yu HA, "Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFRmutant lung cancers", Clin Cancer Res, 19, pp.2240~2247 (2013)
7. Tseng JS, "The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M", Oncotarget, 7, pp.48059~48069 (2016)
8. Hata A, "Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI", J Thorac Oncol, 10, pp.1553~1559 (2015)
9. Goss G, "Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study", Lancet Oncol, 17, pp.1643~1652 (2016)
10. Janne PA, "AZD9291 in EGFR inhibitor-resistant nonsmall-cell lung cancer", N Engl J Med, 372, pp.1689~1699 (2015)
11. Yang JC, "Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA Study phase II extension component", J Clin Oncol, 35, pp.1288~1296 (2017)
12. Edge SB, "AJCC cancer staging handbook. 7th ed." (2009), Springer
13. Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
14. Su KY, "Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer", J Clin Oncol, 30, pp.433~440 (2012)
15. Chang GC, "Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer: a multicenter retrospective SEQUENCE study", Lung Cancer, 104, pp.58~64 (2017)
16. Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
17. Mok TS, "Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer", N Engl J Med, 376, pp.629~640 (2017)
18. Hata AN, "Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition", Nat Med, 22, pp.262~269 (2016)
19. Chen LY, "Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: a systematic review and meta-analysis", Lung Cancer, 94, pp.46~53 (2016)
20. Liu Y, "Metaanalysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs", Onco Targets Ther, 10, pp.2267~2279 (2017)
21. Matsuo N, "Association of EGFR exon 19 deletion and EGFR-TKI treatment duration with frequency of T790M mutation in EGFR-mutant lung cancer patients", Sci Rep, 6, pp.36458~ (2016)
22. [URL]
23. Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
24. Sugio K, "Prospective phase II study of gefitinib in nonsmall cell lung cancer with epidermal growth factor receptor gene mutations", Lung Cancer, 64, pp.314~318 (2009)
25. Shaw AT, "Crizotinib versus chemotherapy in advanced ALK-positive lung cancer", N Engl J Med, 368, pp.2385~2394 (2013)
26. Solomon BJ, "First-line crizotinib versus chemotherapy in ALK-positive lung cancer", N Engl J Med, 371, pp.2167~2177 (2014)
27. Zheng D, "Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance", Sci Rep, 6, pp.20913~ (2016)
28. Siravegna G, "Integrating liquid biopsies into the management of cancer", Nat Rev Clin Oncol, 14, pp.531~548 (2017)
29. Oxnard GR, "Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer", J Clin Oncol, 34, pp.3375~3382 (2016)
30. Tseng JS, "Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma", J Thorac Oncol, 10, pp.603~610 (2015)

관련 논문AI추천